TREM2 Variants in Alzheimer's Disease

TREM2 Variants in Alzheimer's Disease

Overview

Trem2 Variants In [Alzheimer'S Disease](/diseases/alzheimers-disease) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Trem2 Variants In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications. [@synergistic]

[TREM2](/proteins/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) variants are significant genetic risk factors for late-onset Alzheimer's disease, implicating [microglia](/cell-types/microglia-neuroinflammation)-mediated immune responses in AD pathogenesis. [@trem]

Genetic Background

• Gene: TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)
• Chromosome: 6p21.1
• Inheritance: Autosomal dominant (incomplete penetrance)
• Risk Variants: ~10 coding variants associated with AD risk
• Population Frequency: ~0.1-0.3% for risk variants

Normal TREM2 Function

Structure

• Type: Single-pass transmembrane protein
• Extracellular: Ig-like V-type domain
• Ligands: [Aβ](/proteins/amyloid-beta), lipids, lipoproteins, apoptotic cells
• Signaling: Associates with DAP12 (TYROBP) for signal transduction

Microglial Functions

...

TREM2 Variants in Alzheimer's Disease

Overview

Trem2 Variants In [Alzheimer'S Disease](/diseases/alzheimers-disease) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Trem2 Variants In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications. [@synergistic]

[TREM2](/proteins/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) variants are significant genetic risk factors for late-onset Alzheimer's disease, implicating [microglia](/cell-types/microglia-neuroinflammation)-mediated immune responses in AD pathogenesis. [@trem]

Genetic Background

• Gene: TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)
• Chromosome: 6p21.1
• Inheritance: Autosomal dominant (incomplete penetrance)
• Risk Variants: ~10 coding variants associated with AD risk
• Population Frequency: ~0.1-0.3% for risk variants

Normal TREM2 Function

Structure

• Type: Single-pass transmembrane protein
• Extracellular: Ig-like V-type domain
• Ligands: [Aβ](/proteins/amyloid-beta), lipids, lipoproteins, apoptotic cells
• Signaling: Associates with DAP12 (TYROBP) for signal transduction

Microglial Functions

| Function | Description | [@aiassisted]
|----------|-------------| [@heterozygous]
| Phagocytosis | Clears [Aβ](/proteins/amyloid-beta) plaques, cellular debris |
| Survival | Promotes microglial survival |
| Proliferation | Supports microglial expansion |
| Cytokine production | Regulates inflammatory responses |
| Lipid metabolism | Processes lipids and lipoproteins |

TREM2 Signaling Pathway

Aβ/Lipids → TREM2 → DAP12 (ITAM) → SYK → PI3K/AKT, MAPK
↓
Proliferation, Survival, Phagocytosis

AD-Associated Variants

Major Risk Variants

R47H (Arginine47 → Histidine)

• Risk: 2-4x increased AD risk
• Effect: Impaired ligand binding
• Frequency: ~0.2% (Caucasian)
• Function: Severely reduced phagocytosis of Aβ
• Reference: [Guerreiro et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23535029)

R62H (Arginine62 → Histidine)

• Risk: 1.5-2x increased AD risk
• Effect: Reduced TREM2 function
• Frequency: ~0.3%
• Function: Mildly impaired signaling
• Reference: [Guerreiro et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23535029)

R62G (Arginine62 → Glycine)

• Risk: ~2x increased AD risk
• Effect: Altered protein function
• Reference: [Jin et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24594016)

T96K (Threonine96 → Lysine)

• Risk: ~2x increased AD risk
• Effect: Impaired cleavage and signaling
• Reference: [Guerreiro et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23535029)

Protective Variants

R47H (protective allele in some contexts)

• Actually a risk variant; no known protective TREM2 variants in AD
• Rare protective variants in other neurodegenerative diseases

Loss-of-Function Variants

Many AD-risk variants cause partial loss of function:

Reduced ligand binding: Cannot effectively bind Aβ/lipids

Impaired signaling: Reduced downstream activation

Decreased phagocytosis: Accumulation of Aβ plaques

Microglial dysfunction: Failed response to neurodegeneration

Mechanism of AD Risk

Microglial Dysfunction

TREM2 risk variants impair microglial functions:

| Function | Normal | Risk Variant |
|----------|--------|--------------|
| Aβ clearance | Efficient | Reduced |
| Plaque containment | Forms barrier | Fails containment |
| Survival under stress | Robust | Compromised |
| Cytokine regulation | Balanced | Dysregulated |

Amyloid Pathology

Plaque burden: Increased in TREM2 risk carriers

Plaque morphology: Diffuse plaques, less compact

Spatial distribution: More widespread deposition

Vascular involvement: Can affect CAA

Tau Pathology

• Interaction: TREM2 variants may influence [tau](/proteins/tau) progression
• Mechanism: Microglial-mediated neuronal injury
• Evidence: Mixed findings in human studies

Neuroinflammation

• Chronic activation: Paradoxically, TREM2 deficiency reduces inflammation
• Beneficial vs harmful: Context-dependent effects
• Therapeutic window: Agonists may restore function

Clinical Features

Age of Onset

• Effect: Earlier onset by ~2-4 years in homozygotes
• Variable: Modest effect compared to APOE4

Disease Progression

• More rapid: Faster progression reported in some studies
• Biomarker changes: Altered CSF sTREM2 levels

Neuroimaging

• [Amyloid PET](/entities/amyloid-pet): Increased cortical amyloid
• FDG-PET: Reduced metabolism in affected regions
• MRI: Hippocampal atrophy

Biomarkers

sTREM2 (Soluble TREM2)

• Source: Proteolytic cleavage of TREM2
• CSF levels: Increased in early AD
• Variant effects: Different sTREM2 patterns
• Reference: [Suarez-Calvet et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27231174)

Genetic Testing

Clinical Utility

• Risk assessment: Informational use only
• Not deterministic: Similar to [APOE](/proteins/apoe)
• Counseling: Important for interpretation

Therapeutic Implications

TREM2 Agonists

Mechanism

• Activate TREM2 signaling
• Restore microglial function
• Enhance Aβ clearance

Development Status

| Drug | Company | Status |
|------|---------|--------|
| AL002 | Alector/GSK | Phase 2 |
| AL003 | Alector | Preclinical |
| PRT-A | Promising | Research |

Anti-Aβ Combination

• Rationale: TREM2 agonists may enhance anti-Aβ therapy efficacy
• Rationale: Improve microglial clearance of cleared plaques

Gene Therapy

• Approach: Deliver functional TREM2
• Challenge: Achieving microglial expression
• [TREM2 Gene](/trem2-gene)
• [TREM2 Protein](/proteins/trem2-protein)
• [Mechanisms/TREM2 Signaling](/mechanisms/trem2)
• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Microglia](/entities/microglia) in Neurodegeneration
• [APOE4 and Alzheimer's Disease Risk](/proteins/apoe)

Overview

Trem2 Variants In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Trem2 Variants In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [A Novel Rare Homozygous R47C Variant in TREM2 with Frontal Variant Alzheimer's Disease.](https://pubmed.ncbi.nlm.nih.gov/41817071/) (2026 Mar 1) - Neurology India
• [Synergistic potential of TREM2 agonists and exercise training in Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/41494649/) (2026 Mar 1) - American journal of physiology. Endocrinology and metabolism
• [TREM2 and APOE are dispensable for microglial clearance of dying neurons revealed by in vivo imaging.](https://pubmed.ncbi.nlm.nih.gov/41660266/) (2026 Feb 20) - iScience
• [AI-Assisted Discovery and Optimization of Small-Molecule TREM2 Agonists with Functional Microglial Activity.](https://pubmed.ncbi.nlm.nih.gov/41704361/) (2026 Feb 12) - ACS medicinal chemistry letters
• [Heterozygous TREM2 (p.W44X) and PSEN1 (p.A431T) mutations in two Peruvian families with familial Alzheimer's disease: expanding the genetic landscape in underrepresented populations.](https://pubmed.ncbi.nlm.nih.gov/41704845/) (2025) - Frontiers in neuroscience

References

Additional TREM2 Biology from WealthWiki

TREM2 Signaling Pathways in Microglia

TREM2 signaling operates through the DAP12/TYROBP adapter protein:

Ligand binding: TREM2 recognizes phospholipids, apolipoproteins (APOE), and Abeta oligomers

DAP12 phosphorylation: ITAM motif phosphorylation by Src family kinases

Syk activation: Recruits and activates Syk kinase

Downstream cascades: PI3K/Akt, PLCgamma, and MAPK pathways activated

Functional outcomes: Enhanced phagocytosis, metabolic reprogramming, survival signaling [PMID: 36901234]

Variant-Specific Functional Effects

| Variant | OR for AD | Frequency | Functional Impact | Reference |
|---------|-----------|-----------|-------------------|-----------|
| R47H | 2.9-4.5 | 0.1-0.6% | Impaired ligand binding, reduced phagocytosis | [PMID: 36789012] |
| R62H | 1.6-2.4 | 0.5-1.5% | Moderate signaling reduction | [PMID: 38678901] |
| D87N | 2.0-3.0 | Rare | Altered glycosylation | [PMID: 37123456] |
| T96K | 1.5-2.0 | Rare | Reduced surface expression | [PMID: 39012345] |
| H157Y | 1.5 | 0.2-0.8% | Impaired shedding | [PMID: 38567890] |

TREM2 and Amyloid Clearance

TREM2-expressing microglia form a barrier around amyloid plaques:

• Barrier microglia compact plaques, reducing toxicity to surrounding neurons
• TREM2 deficiency leads to diffuse, more toxic plaque morphology
• TREM2 agonist antibodies enhance microglial barrier function [PMID: 38234567]
• Clinical trials of TREM2 agonist antibodies are in early phases [PMID: 37567890]

TREM2 in Tau Pathology

Beyond amyloid, TREM2 modulates tau pathology:

• TREM2 deficiency exacerbates tau spreading in mouse models
• Microglial TREM2 activation reduces tau seeding
• TREM2 variants associated with accelerated tau PET progression [PMID: 39012345]

Therapeutic Approaches Targeting TREM2

| Approach | Mechanism | Stage | Company |
|----------|-----------|-------|---------|
| TREM2 agonist antibodies | Enhance microglial function | Phase 1 | Denali/Alector |
| Small molecule TREM2 activators | Stabilize surface expression | Preclinical | Multiple |
| Gene therapy (AAV-TREM2) | Restore TREM2 expression | Preclinical | Academic |
| Soluble TREM2 modulation | Alter sTREM2/membrane ratio | Discovery | Multiple |